title: Should the Pharmaceutical Benefits Advisory Committee extend the range of free nicotine replacement therapies available for Aboriginal and Torres Strait Islander people?
authors.forename: Jan A
authors.initials: JA
authors.lastname: Robertson
authors.forename: David J
authors.initials: DJ
authors.lastname: MacLaren
authors.forename: Alan R
authors.initials: AR
authors.lastname: Clough
mesh_terms: D000279:Administration, Cutaneous; D026683:Advisory Committees / Q000191:economics*; D001315:Australia / Q000453:epidemiology; D006801:Humans; D009313:National Health Programs / Q000458:organization & administration*; D009538:Nicotine / Q000008:administration & dosage / Q000600:supply & distribution*; D012867:Skin; D012907:Smoking / Q000191:economics / Q000208:ethnology; D000074606:Smoking Prevention
chemical_list: D009538:Nicotine